IMVT News and Press, Immunovant Inc. From 12/20/23

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical tri...

2023-12-20 12:00:32 ET Summary Liquidia Corporation is worth at least $15 in a win. Roivant Sciences is worth at least $12 per share. Burford Capital Limited is worth at least $20 per share. Value & Event Driven Investing I recently spoke for a half an hour a...

2023-12-20 08:36:29 ET Losers: Bluebird bio BLUE -52% on pricing of $125 million stock offering . Jin Medical International Ltd ( ZJYL ) -14% . Argen X SE ( ARGX ) -25% reports topline results from address study of Efgartigimod SC in Pemphigus . ...

2023-12-14 12:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-05 14:25:03 ET Summary Analyzing 13F filings can provide a comprehensive overview of market sentiment and provide a stronger basis for making better-informed investment decisions. Today, we analyze and aggregate 13F filings from the end of the third quarter, seeking o...

2023-11-28 15:30:17 ET More on Immunovant Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrad...

Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 study IMVT-1402 600 mg was observed to deliver ...

Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 study IMVT-1402 600 mg was observed to deliver ...

2023-11-22 17:09:08 ET Gainers: Aurora Innovation ( AUR ) +2% . Innodata  ( INOD ) +2% . The Vita Coco Company ( COCO ) +2% . Immunovant ( IMVT ) +2% . The RealReal ( REAL ) +2% . Losers: BioCryst Pharmaceuticals ( ...

2023-11-14 03:48:37 ET Summary Immunovant continues to show promising developments in anti-FcRn platform's clinical trials and has a strong financial position. Key upcoming catalysts, including Phase 1 data and Phase 2 results, could significantly impact the company's valuation an...